Menu

Recent Interviews

Jared Scharf, CEO, Desert Gold Ventures Inc.

Jared Scharf
CEO | Desert Gold Ventures Inc.
4770 72nd St,, V4K 3N3 Delta (CAN)

jared.scharf@desertgold.ca

Desert Gold Ventures CEO Jared Scharf on West Africa and its potential


Stephan Dorfmeister, Finance Department, Deep Nature Project GmbH

Stephan Dorfmeister
Finance Department | Deep Nature Project GmbH
Untere Hauptstraße 168, 7122 Gols (AT)

office@deep-nature.at

+43 681 10139055

Like Aurora Cannabis and Canopy Growth, Deep Nature Project GmbH focuses on value chain


Alison Coutts, Executive Chairman, Memphasys Ltd.

Alison Coutts
Executive Chairman | Memphasys Ltd.
30 Richmond Road, 2140 Homebush West (AUS)

alison.coutts@memphasys.com

+61 2 8415 7300

Memphasys Executive Chairman Alison Coutts on in vitro fertilisation (IVF)


19. November 2019 | 07:35 CET

Expedeon AG before sale of a division to Abcam plc

  • Medical

The medical research company Expedeon has offices in Heidelberg and Madrid and develops innovative technologies, products and services that are used in research laboratories worldwide. Expedeon's products enable scientists to break down the boundaries of research and product development and make a significant contribution to the market launch of new diagnostic tools. With applications that cover the entire genomics, proteomics and immunology workflow, the technologies developed by Expedeon accelerate and simplify research and enable both biopharmaceutical and diagnostic companies and organizations to introduce new and cost-effective processes. Expedeon's products are distributed through direct sales and several distributors in Europe, the USA and Asia. The company has offices in Germany, Spain, United Kingdom, USA and Singapore.

time to read: 2 minutes by Mario Hose


 

Cash inflow through transaction

On November 11, 2019 Expedeon AG reached an agreement with the online antibody distributor Abcam plc on the planned sale of the immunology and proteomics businesses. Should the deal be approved at the extraordinary general meeting scheduled for December 19, 2019, the transaction is expected to close on January 1, 2020.

According to the agreement, a purchase price of EUR 120 million in cash is to be paid for the acquisition of the two businesses, whereby an amount of EUR 105.6 million is due for immediate payment and a balance of EUR 14.4 million is to be paid over a period of two years.

Acquisitions before successful disposal

The business segments that are thus up for sale were acquired by Expedeon AG in the past financial years as part of the intensive M&A activities. The electrophoresis supplier C.B.S. Scientific was acquired at the end of 2016, starting with the acquisition of the proteomics specialist Expedeon in 2016, which has since given its name to the company. These acquisitions were followed by the acquisition of Innova Biosciences (2017) and TGR Biosciences (2018), both active in the field of protein measurement.

In total, the purchase price of these four companies amounts to EUR 39.8 million and is thus well below the sales price of around EUR 120.0 million that has now been achieved. The current market capitalisation of Expedeon AG at a share price of EUR 1.62 is EUR 84.73 million and would also be significantly exceeded by the purchase price.

Turnover drops after exit

According to the reports of GBC Research, the businesses and products held for sale are responsible for around 90% of annual Expedeon sales and should make a clearly positive contribution to earnings. With annual sales of these products expected to reach around EUR 14.4 million in 2019, this would result in a purchase price multiple of more than 8.

With regard to the key operating figures, the coming financial year would be characterised by the loss of most of the sales revenue and earnings contribution. In 2020, the company is expected to report only about 10% of the current sales level, i.e. around EUR 1.6 to 2.0 million.

Cash per share exceeds market price

Should the transaction be brought to a successful closing, as the experts at GBC Research assume, Expedeon AG would have liquid assets of EUR 120 million, which would provide considerable financial leeway. This would amount to a liquidity of EUR 2.29 per share.

Until the experts at GBC can make a concrete assessment of the remaining business, they will also confirm their previous price target of EUR 3.20 per share. They continue to award the Rating BUY.


Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold shares in the aforementioned companies and that there may therefore be a conflict of interest. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

05. May 2020 | 08:33 CET

Evotec, Medigene, Memphasys - the right investment timing

  • Medical

The health sector has been in the focus of investors not only since the outbreak of the corona pandemic. The pursuit of a healthy and long life is the motivation for research and development around the globe. In addition to Europe and the USA, Australia as a continent is also a location for ideas and innovations. Investors usually always ask the same questions. How expensive and how long does it take to develop the drug or solution and how big is the market. The bigger the problem or need to be treated, the more lucrative it is.

Read

24. April 2020 | 07:36 CET

BioNTech, Gilead, Memphasys - in the spotlight of investors overnight

  • Medical

There are topics and products that are the focus of general interest overnight. Often these are needs or problems that require a time-critical solution. The current situation surrounding the spread of the Corona Virus COVID-19 has brought numerous companies into the focus of investors in recent weeks. The backgrounds are of a very different nature. On the one hand, there are manufacturers of masks, disinfectants or respiratory equipment, as well as medical companies that may have an active ingredient for the prevention or therapy of the Corona Virus on offer. But there are also topics that are beyond the general interest and represent a huge market.

Read

04. March 2020 | 07:27 CET

Medigene, Memphasys, Qiagen - which stocks belong in the portfolio?

  • Medical

In times of price fluctuations, so-called 'buy on dips' strategy can be an effective method of achieving a favorable entry price for listed companies. Global trends as a framework can be decisive for a successful investment decision. For a modern society, the healthcare sector has become a particularly important sector. In addition to the desire for a long life with health and care, there is also an increasing demand for products and therapies that can fulfil couples' desire to have children. There is a broad spectrum and as an investor it is worth taking a look at the companies.

Read